Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 2, 2010, Pages 631-636

  Kagaya, Hideaki ^a   Miura, Masatomo ^a   Saito, Mitsuru ^b   Habuchi, Tomonori ^b   Satoh, Shigeru ^b,c  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXIDOREDUCTASE; PREDNISOLONE; TACROLIMUS; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IMPDH1 PROTEIN, HUMAN; INOSINATE DEHYDROGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ACUTE DISEASE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG COMBINATION; ENZYMOLOGY; GENETICS; GRAFT REJECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; YOUNG ADULT;

EID: 77954733570     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00542.x     Document Type: Article

References (28)

1. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000 47 : 215 245.
2. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001 23 : 305 315.
3. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 : 145 154. (Pubitemid 44314941)
4. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998 64 : 672 683.
5. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 13 : 759 768.
6. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003 25 : 137 157.
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007 46 : 13 58.
8. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000 38 : 1213 1216.
9. Budde K, Braun KP, Glander P, Böhler T, Hambach P, Fritsche L et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplant Proc 2002 34 : 1748 1750.
10. Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006 66 : 31 44.
11. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004 4 : 2045 2051.
12. Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000 46 : 1376 1383.
13. Digits JA, Hedstrom L. Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 1999 38 : 15388 15397.
14. Futer O, Sintchak MD, Caron PR, Nimmesgern E, DeCenzo MT, Livingston DJ et al. A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase. Biochim Biophys Acta 2002 1594 : 27 39.
15. McPhillips CC, Hyle JW, Reines D. Detection of the mycophenolate- inhibited form of IMP dehydrogenase in vivo. Proc Natl Acad Sci USA 2004 101 : 12171 12176.
16. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007 7 : 312 317.
17. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008 83 : 711 717.
18. Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008 8 : 1237 1249.
19. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi 2006 126 : 1357 1362.
20. Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006 82 : 486 493.
21. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007 63 : 279 288. (Pubitemid 46233156)
22. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008 86 : 1043 1051.
23. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004 4 : 1079 1083.
24. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009 19 : 626 634.
25. van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009 86 : 319 327.
26. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005 78 : 351 361.
27. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006 6 : 63 75.
28. Inoue K, Miura M, Satoh S, Kagaya H, Saito M, Habuchi T et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007 29 : 299 304. (Pubitemid 47262259)